It is time to contend with the endothelial consequences of prehypertension

Journal of Human Hypertension

Volumn 29, Issue 8, 2015, Pages 457-458

  Van Guilder, G P ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ATHEROGENESIS; BODY COMPOSITION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY CALCIFICATION; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; ELEVATED BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORTALITY; NOTE; PREHYPERTENSION; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VEIN OCCLUSION PLETHYSMOGRAPHY; MALE; METABOLISM;

ENDOTHELIUM, VASCULAR; HUMANS; MALE; PREHYPERTENSION; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84936845635     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.122     Document Type: Note

References (15)

1. World Health Organization. Global Status Report on Noncommunicable Diseases 2010. World Health Organization: Geneva, Switzerland, 2010.
2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2224-2260.
3. Olives C, Myerson R, Mokdad AH, Murray CJ, Lim SS. Prevalence, awareness, treatment, and control of hypertension in United States counties, 2001-2009. PLoS ONE 2013; 8(4): e60308.
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2014 update: a report from the american heart association. Circulation 2014; 129(3): e28-e292.
5. Lawes CM, Vander Hoorn S, Rodgers A. International Society of H. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371(9623): 1513-1518.
6. Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, et al. The Global Economic Burden of Non-communicable Diseases 2011. Available at http://www3.weforum.org/docs/WEF-Harvard-HE-GlobalEconomic BurdenNonCommunicableDiseases-2011.pdf, accessed on 3 November 2014.
7. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123(8): 933-944.
8. Robinson SC, Brucer M. Range of normal blood pressure: a statistical and clinical study of 11,383 persons. Arch Intern Med 1939; 64(3): 409-444.
9. Huang Y, Su L, Cai X, Mai W, Wang S, Hu Y, et al. Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis. Am Heart J 2014; 167(2): 160-168 e161.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-2572.
11. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349):1903-1913.
12. Diehl KJ, Weil BR, Greiner JJ, Wright KP Jr, Stauffer BL, DeSouza CA. Impaired endogenous fibrinolytic capacity in prehypertensive men. J Hum Hypertens 2015; 29: 468-472.
13. Robinson SD, Ludlam CA, Boon NA, Newby DE. Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2007; 27(7): 1651-1656.
14. Papadopoulos D, Mourouzis I, Kotrotsou A, Papazachou U, Sanidas E, Tsioufis K, et al. Hemostasis parameters disturbances in healthy individuals with prehypertension. Clin Exp Hypertens 2012; 34(6): 385-388.
15. Hrafnkelsdottir T, Wall U, Jern C, Jern S. Impaired capacity for endogenous fibrinolysis in essential hypertension. Lancet 1998; 352(9140): 1597-1598.